fig1

Figure 1. Design of a drug screening system against miPSCs-derived CSCs (miPS-CSCs). A: Schematic representation of drug screening against miPS-CSCs. Stem cell populations of miPS-CSCs were concentrated in the presence of puromycin and CM of bulk culture. Drug screening was performed under treatment with CMs. Each test compound was added at a concentration of 1 μmol/L. Cell viability was determined by MTT assay after 48 h of treatment; B: representative results of screening with compounds categorized as anticancer drugs (n = 2). The miPS-LLCcm, miPS-LLCcm primary, miPS-LLCcm LMT, and miPS-B16cm cell lines were used for the screening. Relative cell viabilities were presented as normalized values against DMSO control; C: IC50 values of daunorubicin against various miPS-LLCcm were determined. BALB/c 3T3 cells, L1210s cells, Hela cells, and miPSCs were additionally tested for comparison